TWI318116B - Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents - Google Patents

Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents

Info

Publication number
TWI318116B
TWI318116B TW096138754A TW96138754A TWI318116B TW I318116 B TWI318116 B TW I318116B TW 096138754 A TW096138754 A TW 096138754A TW 96138754 A TW96138754 A TW 96138754A TW I318116 B TWI318116 B TW I318116B
Authority
TW
Taiwan
Prior art keywords
prophylaxis
viral
treatment
pharmaceutical compositions
protease inhibitors
Prior art date
Application number
TW096138754A
Other languages
English (en)
Chinese (zh)
Other versions
TW200804252A (en
Inventor
Robin Hale Michael
Tung Roger
Price Stephen
David Wilkes Robin
Carl Schairer Wayne
Nicholas Jarvis Ashley
Spaltenstein Andrew
Steven Furfine Eric
Samano Vicente
Kaldor Istvan
Franklin Miller John
Stephen Brieger Michael
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of TW200804252A publication Critical patent/TW200804252A/zh
Application granted granted Critical
Publication of TWI318116B publication Critical patent/TWI318116B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
TW096138754A 1999-06-11 2000-06-08 Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents TWI318116B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13907099P 1999-06-11 1999-06-11
US19021100P 2000-03-17 2000-03-17

Publications (2)

Publication Number Publication Date
TW200804252A TW200804252A (en) 2008-01-16
TWI318116B true TWI318116B (en) 2009-12-11

Family

ID=26836833

Family Applications (3)

Application Number Title Priority Date Filing Date
TW089111145A TW593248B (en) 1999-06-11 2000-06-08 Inhibitors of aspartyl protease
TW096138754A TWI318116B (en) 1999-06-11 2000-06-08 Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents
TW093114799A TWI299000B (en) 1999-06-11 2000-06-08 Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW089111145A TW593248B (en) 1999-06-11 2000-06-08 Inhibitors of aspartyl protease

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW093114799A TWI299000B (en) 1999-06-11 2000-06-08 Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents

Country Status (31)

Country Link
EP (2) EP1194404B1 (xx)
JP (2) JP4503896B2 (xx)
KR (1) KR100762188B1 (xx)
CN (2) CN100516034C (xx)
AR (1) AR031520A1 (xx)
AT (2) ATE534622T1 (xx)
AU (1) AU779994B2 (xx)
BR (1) BR0011745A (xx)
CA (1) CA2380858C (xx)
CO (1) CO5160337A1 (xx)
CY (1) CY1112632T1 (xx)
CZ (1) CZ303052B6 (xx)
DE (1) DE60027722T2 (xx)
DK (2) DK1686113T3 (xx)
ES (2) ES2375823T3 (xx)
HK (1) HK1046899B (xx)
HU (1) HUP0300385A3 (xx)
IL (3) IL146918A0 (xx)
MX (1) MXPA01012808A (xx)
MY (1) MY137777A (xx)
NO (1) NO323951B1 (xx)
NZ (1) NZ516003A (xx)
PE (1) PE20010230A1 (xx)
PL (1) PL210227B1 (xx)
PT (2) PT1686113E (xx)
SI (1) SI1194404T1 (xx)
TN (1) TNSN00129A1 (xx)
TR (3) TR200200407T2 (xx)
TW (3) TW593248B (xx)
WO (1) WO2000076961A1 (xx)
ZA (1) ZA200110177B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065870A2 (en) 1998-06-19 1999-12-23 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
ATE343567T1 (de) 2001-02-14 2006-11-15 Tibotec Pharm Ltd Breitspektrum 2-(substituierte-amino)- benzothiazol-sulfonamide hiv protease inhibitoren
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
MY142238A (en) * 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
AU2003231766A1 (en) * 2002-04-26 2003-11-10 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
JP2007521277A (ja) * 2003-06-27 2007-08-02 スミスクライン ビーチャム コーポレーション 化合物の製造
US7767683B2 (en) 2003-08-18 2010-08-03 H. Lundbeck A/S Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament
CN102627609B (zh) * 2003-12-15 2016-05-04 默沙东公司 杂环天冬氨酰蛋白酶抑制剂
CN1953964A (zh) 2004-03-11 2007-04-25 塞阔伊亚药品公司 抗耐药性反转录病毒蛋白酶抑制剂
TWI383975B (zh) 2004-03-31 2013-02-01 Tibotec Pharm Ltd 製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
JP2008533017A (ja) * 2005-03-11 2008-08-21 スミスクライン ビーチャム コーポレーション Ｈｉｖプロテアーゼ阻害薬
US8227450B2 (en) 2005-11-30 2012-07-24 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
EP2069356A1 (en) * 2006-07-24 2009-06-17 Gilead Sciences, Inc. Bisfuranyl protease inhibitors
PL2089371T3 (pl) 2006-11-09 2011-06-30 Janssen Sciences Ireland Uc Sposoby wytwarzania heksahydrofuro[2,3-b]furan-3-olu
EP2120562A4 (en) * 2006-11-21 2010-01-13 Purdue Research Foundation METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS
PT2152667E (pt) 2007-04-27 2011-04-06 Tibotec Pharm Ltd Processos para a preparação de derivados de n-isobutil-n- (2-hidroxi-3-amino-4-fenilbutil)-p-nitrobenzenosulfonilamida
GB2452952A (en) * 2007-09-20 2009-03-25 Npil Pharmaceuticals N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
MX2012003424A (es) 2009-09-22 2012-05-08 Tibotec Pharm Ltd Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
CN103193570B (zh) * 2013-04-09 2014-01-22 湖北来凤腾升香料化工有限公司 一种羟基高选择性保护方法
JPWO2016039403A1 (ja) * 2014-09-11 2017-06-29 塩野義製薬株式会社 持続性ｈｉｖプロテアーゼ阻害剤
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
HU9301447D0 (en) * 1990-11-19 1993-11-29 Monsanto Co Inhibitors of retrovirus protease
US5475013A (en) * 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
KR100336699B1 (ko) * 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
CA2143191A1 (en) * 1992-10-30 1994-05-11 Michael L. Vazquez Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
ES2127938T3 (es) * 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
CA2210889C (en) * 1995-01-20 2007-08-28 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
PL184771B1 (pl) * 1995-03-10 2002-12-31 Searle & Co Związek stanowiący hydroksyetyloaminosulfonamid pirolidynokarbonyloaminokwasu, kompozycja zawierająca ten związek, jego zastosowanie do wytwarzania kompozycji do leczenia infekcji retrowirusowej i sposób zapobiegania replikacji retrowirusa in vitro
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
AU7722296A (en) * 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
GB9712504D0 (en) * 1997-06-17 1997-08-20 Dundee Teaching Hospitals Nhs Thermal imaging method and apparatus
US6316405B1 (en) * 1997-08-26 2001-11-13 Wisconsin Alumni Research Foundation Cyclosporin a conjugates and uses therefor
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion

Also Published As

Publication number Publication date
CA2380858C (en) 2011-12-06
CA2380858A1 (en) 2000-12-21
KR100762188B1 (ko) 2007-10-04
PL210227B1 (pl) 2011-12-30
AU5600600A (en) 2001-01-02
IL146918A0 (en) 2002-08-14
JP4503896B2 (ja) 2010-07-14
HUP0300385A2 (hu) 2003-07-28
CN100516034C (zh) 2009-07-22
DK1194404T3 (da) 2006-09-04
NO323951B1 (no) 2007-07-23
ES2375823T3 (es) 2012-03-06
TW200804252A (en) 2008-01-16
HK1046899A1 (en) 2003-01-30
ATE325091T1 (de) 2006-06-15
EP1686113B1 (en) 2011-11-23
IL202633A0 (en) 2010-06-30
CN1361765A (zh) 2002-07-31
EP1194404B1 (en) 2006-05-03
NO20016034L (no) 2002-01-18
BR0011745A (pt) 2002-03-19
PT1194404E (pt) 2006-08-31
TNSN00129A1 (fr) 2005-11-10
TR200200407T2 (tr) 2002-08-21
PT1686113E (pt) 2012-02-20
PL352830A1 (en) 2003-09-08
HUP0300385A3 (en) 2007-05-29
NO20016034D0 (no) 2001-12-10
CN101245058A (zh) 2008-08-20
TW593248B (en) 2004-06-21
CZ20014431A3 (cs) 2002-06-12
TW200425891A (en) 2004-12-01
JP2003502309A (ja) 2003-01-21
CZ303052B6 (cs) 2012-03-14
ES2263478T3 (es) 2006-12-16
TR200202528T2 (tr) 2003-02-21
SI1194404T1 (sl) 2006-10-31
EP1686113A1 (en) 2006-08-02
TWI299000B (en) 2008-07-21
DE60027722T2 (de) 2007-04-26
HK1046899B (zh) 2007-03-02
EP1194404A1 (en) 2002-04-10
DE60027722D1 (en) 2006-06-08
WO2000076961A1 (en) 2000-12-21
AR031520A1 (es) 2003-09-24
MY137777A (en) 2009-03-31
ZA200110177B (en) 2003-01-13
AU779994B2 (en) 2005-02-24
DK1686113T3 (da) 2012-02-20
IL146918A (en) 2010-06-16
KR20020033642A (ko) 2002-05-07
NZ516003A (en) 2004-02-27
CO5160337A1 (es) 2002-05-30
PE20010230A1 (es) 2001-03-15
TR200603871T2 (tr) 2007-01-22
IL202633A (en) 2013-02-28
JP2009046493A (ja) 2009-03-05
MXPA01012808A (es) 2002-07-22
CY1112632T1 (el) 2016-02-10
ATE534622T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
TWI318116B (en) Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
AU3413100A (en) Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase
HU9802525D0 (en) Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections
PL344223A1 (en) Compositions for the treatment of hiv and other viral infections
HUP0401730A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
IL191905A0 (en) Inhibitors of serine proteases particularly hepatitis c virus ns3 protease, pharmaceutical compositions containing the same and the use thereof
AU2560000A (en) Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin
AU1101501A (en) Methods and compositions for treatment of keratoconus using protease inhibitors
HUP0201846A3 (en) Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
PL312908A1 (en) Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors
WO2002085358A3 (en) Antiviral agents and methods of treating viral infections
HUP0500164A3 (en) Heterocyclic substituted benzenesulfonamides as hiv protease inhibitors and pharmaceutical compositions containing them
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
WO2002000613A3 (en) Inhibitors of hepatitis b virus infection
IL107755A0 (en) Pharmacuetical compositions for the treatment and prophylaxis of parasitic infections
HK1041444A1 (zh) 用於治療hiv感染的包含peg-天冬酰胺酶的藥物組合物
AP2002002432A0 (en) Treatment of viral infections
SI1173194T1 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
HUP0200466A3 (en) Lipoglycan compositions and methods of treating parasitic infections
AU4650500A (en) Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
AU3524700A (en) Prevention and treatment of viral infections

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees